Evidence map›Paper›PMID 38038883›Full record

ArticleAdvances in therapy2024

Correction to: Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study.

Hiroyuki Nagase, Risako Ito, Moe Ishii, Hideki Shibata, Shintaro Suo, Isao Mukai, Shiyuan Zhang, Kieran J Rothnie, Claire Trennery, Liza Yuanita and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Hiroyuki NagaseDivision of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan. nagaseh@med.teikyo-u.ac.jp.ORCID http://orcid.org/0000-0002-0296-5901
Risako ItoValue Evidence and Outcomes, GSK, 1-8-1 Akasaka, Minato-ku, Tokyo, 107-0052, Japan. risako.2.ito@gsk.com.
Moe IshiiMebix, Inc., Minato-ku, Tokyo, Japan.
Hideki ShibataMebix, Inc., Minato-ku, Tokyo, Japan.
Shintaro SuoMebix, Inc., Minato-ku, Tokyo, Japan.
Isao MukaiMedical Affairs Asthma & COPD, GSK, Minato-ku, Tokyo, Japan.
Shiyuan ZhangValue Evidence and Outcomes, GSK, Collegeville, PA, USA.ORCID http://orcid.org/0000-0001-8523-0419
Kieran J RothnieValue Evidence and Outcomes, GSK, Brentford, Middlesex, UK.
Claire TrenneryValue Evidence and Outcomes, GSK, Brentford, Middlesex, UK.
Liza YuanitaMedical Affairs Asthma & COPD, GSK, Minato-ku, Tokyo, Japan.
Takeo IshiiValue Evidence and Outcomes, GSK, 1-8-1 Akasaka, Minato-ku, Tokyo, 107-0052, Japan.ORCID http://orcid.org/0000-0001-6865-1967

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38038883
PMCPMC10838822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.